Meeting
2021 ASCO Annual Meeting
IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.
Authors
Uwe Platzbecker
Department of Hematology and Cell Therapy, University Clinic Leipzig, Leipzig, Germany
Uwe Platzbecker , Rami S. Komrokji , Pierre Fenaux , Amer Methqal Zeidan , Mikkael A. Sekeres , Michael R. Savona , Yazan Madanat , Laurie Jill Sherman , Souria Dougherty , Libo Sun , Fei Huang , Ying Wan , Aleksandra Rizo , Tymara Berry , Faye Feller , Valeria Santini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Clinical Trial Registration Number
NCT02598661
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7056)
DOI
10.1200/JCO.2021.39.15_suppl.TPS7056
Abstract #
TPS7056
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical outcomes by SF3B1 mutation status in patients (pts) with lower-risk myelodysplastic syndrome (LR-MDS) retreated with erythropoiesis-stimulating agents (ESAs).
First Author: Adeola Y. Makinde
Poster
2021 ASCO Annual Meeting
Choosing unwisely: Low-value care in older adults with a diagnosis of myelodysplastic syndrome.
First Author: Sudipto Mukherjee
Poster
2016 ASCO Annual Meeting
Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).
First Author: Guillermo Garcia-Manero
Poster
2023 ASCO Quality Care Symposium
Clinical and economic effects of technology updates to the electronic health record for the management of erythopoetic stimulating agents and MDS-associated anemia.
First Author: Steven Gilmore